Stockscreener 앱 받기
1.07
3.88%
0.04
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World
NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow
Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com
Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan
NeuroSense Therapeutics Reports 2024 Financial Results - TipRanks
NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment - MSN
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - Quantisnow
Regulatory T-cells (Tregs) Market to Observe Significant Growth by 2034 Owing to the Development in 12+ Indications with Severe and Refractory Patients as the Treatment Addressable Population | DelveInsight - PR Newswire
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan
Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com
NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks
Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com
Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire
Motor Neuron Disease Clinical Pipeline | 180+ Companies Advancing Next-Generation Therapies - openPR.com
NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World
NeuroSense Therapeutics: A Promising Biotech Stock in the Neurodegenerative Space - eng.expertclub.ge
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire
NeuroSense Advances PrimeC Commercialization in Canada - TipRanks
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Marketscreener.com
Breakthrough: NeuroSense ALS Treatment Cuts Disease Progression by 36%, Boosts Survival 43% - StockTitan
The next rare disease roadblock: American innovation moving ex-U.S. - BioCentury
NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment - TipRanks
NeuroSense Therapeutics Reports Key Progress and Financials - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.4% – Here’s What Happened - Defense World
NeuroSense regains Nasdaq compliance with equity boost - Investing.com
NeuroSense regains Nasdaq compliance with equity boost By Investing.com - Investing.com Nigeria
NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment - TipRanks
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - StreetInsider.com
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - GuruFocus.com
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit - GuruFocus.com
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In R - GuruFocus.com
Neurosense Therapeutics Ltd (NRSN-Q) QuotePress Release - The Globe and Mail
Analyzing NeuroSense Therapeutics (NASDAQ:NRSN) & Avidity Biosciences (NASDAQ:RNA) - Defense World
NeuroSense Partners with Pharma Giant to Propel ALS Drug PrimeC - TipRanks
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - Nasdaq
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Shares Bought by XTX Topco Ltd - Defense World
0.39%
3.66%
자본화:
|
볼륨(24시간):